Skip to content
Business
Link copied to clipboard
Link copied to clipboard

GSK, Pfizer to merge their healthcare divisions

Drugmakers GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating a business with combined sales of $12.7 billion.

This Jan. 25, 2009 file photo, shows the sign at Pfizer world headquarters in New York. Drugmakers GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating a business with combined sales of 9.8 billion pounds ($12.7 billion). (AP Photo/Mark Lennihan, File)
This Jan. 25, 2009 file photo, shows the sign at Pfizer world headquarters in New York. Drugmakers GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating a business with combined sales of 9.8 billion pounds ($12.7 billion). (AP Photo/Mark Lennihan, File)Read moreMark Lennihan / AP
    by Associated Press, The Associated Press
    Published 

LONDON (AP) — Drugmakers GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating a business with combined sales of $12.7 billion.

British-based Glaxo will own 68 percent of the joint venture, while U.S.-based Pfizer will own the remaining 32 percent stake.

The joint venture will bring together Glaxo's brands such as Sensodyne, Voltaren and Panadol with Pfizer's Advil and Centrum.

Shareholders have long pressured Glaxo to break itself in two companies — with one focused on pharmaceuticals and vaccines, and the other on consumer healthcare. Glaxo aims to do this within three years.

Emma Walmsley, CEO of Glaxo, says that with the “future intention to separate, the transaction also presents a clear pathway forward for GSK to create a new global pharmaceuticals/vaccines company, with an R&D (research and development) approach.”